Brief: Clover Biopharmaceuticals Says Universal Covid-19 Booster Vaccine Candidate Demonstrates Superior Neutralization Of Omicorn Ba.5
20/09/2022 02:31
Sept 20 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* CO'S UNIVERSAL COVID-19 BOOSTER VACCINE CANDIDATE
DEMONSTRATES
SUPERIOR NEUTRALIZATION OF OMICORN BA.5
Source text for Eikon: ID:nHKS6JQ8hg
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune